Equities Analysts Set Expectations for ENTA FY2029 Earnings

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) – Equities researchers at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Enanta Pharmaceuticals in a research report issued on Tuesday, December 24th. HC Wainwright analyst E. Arce expects that the biotechnology company will post earnings of ($6.62) per share for the year. HC Wainwright has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for Enanta Pharmaceuticals’ current full-year earnings is ($4.73) per share.

Several other equities analysts also recently commented on the stock. Robert W. Baird lowered their price objective on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating for the company in a research note on Tuesday, November 26th. JMP Securities reaffirmed a “market outperform” rating and issued a $21.00 target price (down from $22.00) on shares of Enanta Pharmaceuticals in a research report on Tuesday, November 26th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $17.25.

Enanta Pharmaceuticals Stock Performance

NASDAQ:ENTA opened at $6.10 on Wednesday. Enanta Pharmaceuticals has a fifty-two week low of $5.70 and a fifty-two week high of $17.80. The business has a 50 day moving average price of $9.64 and a 200-day moving average price of $11.66. The firm has a market cap of $129.28 million, a PE ratio of -1.11 and a beta of 0.49.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings data on Monday, November 25th. The biotechnology company reported ($1.36) EPS for the quarter, missing the consensus estimate of ($1.16) by ($0.20). The company had revenue of $14.60 million during the quarter, compared to analysts’ expectations of $17.99 million. Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%. The firm’s quarterly revenue was down 22.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.33) EPS.

Insider Transactions at Enanta Pharmaceuticals

In other news, CEO Jay R. Luly sold 5,142 shares of the business’s stock in a transaction on Friday, December 6th. The stock was sold at an average price of $8.06, for a total value of $41,444.52. Following the completion of the transaction, the chief executive officer now owns 801,638 shares in the company, valued at $6,461,202.28. The trade was a 0.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 13.64% of the company’s stock.

Hedge Funds Weigh In On Enanta Pharmaceuticals

A number of hedge funds have recently bought and sold shares of ENTA. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Enanta Pharmaceuticals during the third quarter valued at approximately $122,000. American Century Companies Inc. raised its position in shares of Enanta Pharmaceuticals by 35.4% during the second quarter. American Century Companies Inc. now owns 27,892 shares of the biotechnology company’s stock valued at $362,000 after buying an additional 7,287 shares during the last quarter. Cubist Systematic Strategies LLC lifted its holdings in shares of Enanta Pharmaceuticals by 65.8% in the second quarter. Cubist Systematic Strategies LLC now owns 45,350 shares of the biotechnology company’s stock worth $588,000 after buying an additional 18,003 shares in the last quarter. Erste Asset Management GmbH bought a new position in shares of Enanta Pharmaceuticals during the third quarter worth $1,243,000. Finally, Point72 Asset Management L.P. purchased a new position in Enanta Pharmaceuticals during the third quarter valued at $903,000. Hedge funds and other institutional investors own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.